Document is current
Any future updates will be listed below
-
Authors
Otani, Yuki https://orcid.org/0000-0002-7184-8776
Payne, Christopher D. https://orcid.org/0000-0003-0549-5455
Loftus, Edward V. Jr. https://orcid.org/0000-0001-7199-6851
D’Haens, Geert https://orcid.org/0000-0003-2784-4046
Ben Horin, Shomron https://orcid.org/0000-0002-3984-4580
Upadhya K, Abhishek https://orcid.org/0009-0007-8835-6093
Todd, Kristin
Pellanda, Paola https://orcid.org/0000-0002-7494-8334
Shi, Galen
Zhang, Xin
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06475729 at ClinicalTrials.govDocuments that mention this clinical trial
One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants
https://doi.org/10.1007/s12325-025-03422-1
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 18 July 2025
Accepted: 28 October 2025
First Online: 28 November 2025
Declarations
:
: Yuki Otani, Christopher D. Payne, Abhishek Upadhya K, Kristin Todd, Paola Pellanda, Galen Shi, and Xin Zhang are employees and shareholders of Eli Lilly and Company. Edward V. Loftus, Jr. has consulted for Abivax, AbbVie, Astellas, Avalo, Biocon, Bristol-Myers Squibb, Celltrion, Eli Lilly, Fresenius Kabi, Genentech, Gilead, Iota Biosciences, Iterative Health, Janssen, Merck, Morphic, Ono Pharma, Spyre, Takeda, and TR1X Bio; has received research support from AbbVie, Genentech, Gilead, Janssen, Merck, and Takeda; and is a shareholder of Exact Sciences and Moderna. Geert D’Haens has been an adviser and/or speaker for Abbvie, Alimentiv, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Galapagos, Glaxo Smith Kline, Immunic, Index Pharmaceuticals, Johnson and Johnson, Merck, Polpharm, Prometheus biosciences, Prometheus Laboratories, Procise Diagnostics, Protagonist, Sanofi, Spyre, Takeda, Tillotts, and Ventyx. Shomron Ben Horin has received advisory board and/or consulting fees from Abbvie, Takeda, Janssen, Celltrion, Pfizer, GSK, Ferring, Novartis, Roche, Gilead, NeoPharm, Predicta Med, Galmed, Medial Earlysign, and Eli Lilly; has stocks/options in Galmed, Evinature, PredictaMed, and Alma Therapeutics; and has received research support from Abbvie, Takeda, Janssen, Celltrion, Pfizer, Medtronic, and Galmed.
: The study was conducted in accordance with principles derived from the Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines, and the International Council on Harmonisation guidelines and with applicable laws and regulations. The study protocol and the consent forms used were approved by the Salus Institutional Review Board, which covered the ethical approval from each site related to this study (I6T-MC-AMCB). Participants provided written informed consent before they entered the study. The informed consent forms outlined why the research was being done and what it would involve, and it noted that study data that did not directly identify participants could be published.
